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Among these ESBL, CTX-M enzymes are the most widespread
in Escherichia coli both in nosocomial and in the community
setting. Moreover, the diffusion of the pandemic clone desig-
nated CTX-M-15-producing E. coli O25b:H4-ST131 has exac-
erbated this situation. This clone has been described in
environment, food, and animals [1]. Even though this clone has
been recently observed in Swiss lakes [2], no report has
described the presence of the pandemic clone ST131 in wild
ﬁsh in the sea.
From March 2012 to February 2013, gut and gills samples
from different ﬁsh caught in the Mediterranean Sea far from
Béjaia (Algeria) were prospectively and randomly collected. All
the ﬁsh were sampled by opening the gut using a sterile scalpel
after washing the gut surface with sterile saline and then
swabbing the contents. To screen for oxyimino-cephalosporin-
resistant (OCR) E. coli, samples were placed in 1 mL sterile
0.9% saline and then vortexed. From this suspension, 100 μL
was plated on two MacConkey agar dishes supplemented with
cefotaxime (2 μg/mL) or ceftazidime (2 μg/mL) incubated for 24
hours at 37 °C under aerobic conditions. A single colony of
E. coli was selected for further study. Bacterial genus and species
were identiﬁed by conventional methods (API 20E; BioMérieux,
Marcy l’Étoile, France). Susceptibility to antimicrobial agentsMicrobiol Infect 2015; 21: e18–e20
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ESBL production was screened by the double-disk synergy test
according to recommendations of the Antibiotic Committee of
the French Society for Microbiology (http://www.sfm-
microbiologie.org). Plasmid DNA was extracted from the iso-
lates using the EZ1 DNA Tissue kit on the BioRobot EZ1
extraction platform (QIAGEN, Courtaboeuf, France). The
genes coding for ESBL (blaTEM, blaSHV, and blaCTX-M) were
detected by PCR using speciﬁc primers and identiﬁed by
sequencing the PCR products [3]. We used a triplex PCR
speciﬁc for the CTX-M-15 producing E. coli O25b:H4-ST131
clone as described previously [4]. The qnrA, qnrB, qnrS, aac(60)-
Ib-cr (identiﬁed by BtsCI digestion), and qepA genes were
screened by PCR in all of the quinolone-resistant isolates and
identiﬁed by sequencing [5,6]. The aac(30)-IV, aac(30)-II, aac(3)-
III, ant(200)-I, and aac(30)-I genes were screened by PCR.
Phylogenetic grouping and the O group of the ESBL-producing
E. coli isolates were determined by PCR-based methods
developed by Clermont et al. [7]. For all multi-drug-resistant
E. coli, the genetic relationship was studied using the Diversi-
Lab system (bioMérieux), a semi-automated ﬁngerprinting tool
based on repetitive sequence-based PCR (Rep-PCR), by
following the manufacturer’s instructions. Isolates with identical
strain patterns were considered indistinguishable if their simi-
larity percentage was 95%. Moreover, multi-locus sequence
typing (MLST) was carried out according to the Institut Pas-
teur’s MLST scheme (http://www.pasteur.fr/mlst) and the
Achtman scheme (http://mlst.ucc.ie/mlst/dbs/Ecoli).
Of the 300 samples analyzed, 22 (7.3%) OCR E. coli isolates
were detected. They were isolated from guts (n = 14) and gills
(n = 8). All the isolates were resistant to cefotaxime, 90.9% to
ceftazidime, and 72.7% to cefepime. Co-resistances to non-
β-lactams were also observed: nalidixic acid (86.4%), oﬂoxacin
(77.3%), ciproﬂoxacin (68.2%), co-trimoxazole (54.5%), kana-
mycin (36.4%), gentamycin (27.3%), netilmicin (22.7%), and
amikacin (4.5%). All the isolates were susceptible to carbape-
nems (Table 1).
The 22 isolates produced an ESBL. The prevalence of CTX-
M-producing E. coli within OCR E. coli isolates was 72.7%
(n = 16). CTX-M-15 was the mainly CTX-M-encoding gene
(93.8%) in our study. One strain harboured blaCTX-M-9 group
gene. The six remaining strains (27.3%) carried TEM-24 en-
zymes (Table 1).
To study the plasmidic co-resistance, we screened the
presence of qnr, aac60-Ib-cr, and qepA genes. The prevalence of
qnr genes was 36.4% of ESBL-producing E. coli strains. qnrB and
qnrS were identiﬁed in 2 (9.1%) and 6 (27.3%) strains, respec-
tively. The qnrB gene was detected in only the two CTX-M-15-
producing isolates, whereas the qnrS determinant was found inious Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 1. Characteristics of ESBL-producing Escherichia coli isolated from wild ﬁsh in Mediterranean Sea near Béjaia, Algeria
Strains Fish species Resistance phenotype
Phylogenetic
group
Sequence type
Achtman
β-lactamase
content
PMQR content and associated
resistance gene
ES1 Boops boops CTX CAZ FEP NAL OFX CIP A ST471 CTX-M-15 –
ES2 Sardina pilchardus CTX CAZ FEP A ST132 CTX-M-15 –
ES3 Sarpa salpa CTX CAZ FEP A ST398 CTX-M-15 –
ES4 Sarpa salpa CTX B1 ST398 CTX-M-15 –
ES5 Sarpa salpa CTX CAZ FEP KNM NAL B1 ST 398 CTX-M-15 aac(30)-IV
ES6 Sarpa salpa CTX CAZ FEP NAL OFX CIP SXT A ST 37 CTX-M-15 qnrS
ES7 Trachurus trachurus CTX CAZ NAL OFX CIP SXT D ST 31 TEM-24 qnrS
ES8 Trachurus trachurus CTX CAZ NAL OFX CIP SXT A ST 471 TEM-24 –
ES9 Pagellus acarne CTX FEP NAL SXT B2 ST 8 CTX-M groupe 9 –
ES10 Pagellus acarne CTX CAZ FEP NET AKN GMI KNM NAL
OFX CIP SXT
D ST 477 CTX-M-15 aac60-Ib-cr; qnrS; aac(30)-IV; aac(30)-II;
aac(30)-I; aac(3)-III
ES11 Pagellus acarne CTX CAZ FEP NET GMI KNM NAL
OFX CIP SXT
B2 ST 131 CTX-M-15 aac60-Ib-cr; qnrB; aac(30)-IV; aac(30)-II;
aac(3)-III
ES12 Pagellus acarne CTX CAZ NAL OFX CIP A ST 471 CTX-M-15 –
ES13 Pagellus acarne CTX CAZ FEP NET GMI KNM NAL
OFX CIP SXT
B2 ST131 CTX-M-15 aac60-Ib-cr; qnrB; aac(30)-IV; aac(30)-II;
aac(3)-III; ant(200)-I
ES14 Pagellus acarne CTX CAZ FEP NAL OFX CIP A ST 471 CTX-M-15 –
ES15 Pagellus acarne CTX CAZ FEP NET GMI KNM NAL
OFX CIP SXT
D ST477 CTX-M-15 aac60-Ib-cr; qnrS; aac(30)-II; aac(3)-III
ES16 Pagellus acarne CTX CAZ FEP NAL OFX CIP A ST471 TEM-24 aac60-Ib-cr; qnrS
ES17 Pagellus acarne CTX CAZ NAL OFX CIP SXT B1 ST 21 TEM-24 –
ES18 Pagellus acarne CTX CAZ FEP GMI KNM NAL OFX
CIP SXT
A ST66 TEM-24 –
ES19 Sardina pilchardus CTX CAZ FEP KNM NAL OFX CIP D ST31 CTX-M-15 qnrS; aac(30)-IV; aac(3)-III; ant(200)-I
ES20 Sardina pilchardus CTX CAZ NET GMI NAL OFX A ST 74 TEM-24 –
ES21 Sardina pilchardus CTX CAZ FEP KNM NAL OFX CIP SXT A ST 471 CTX-M-15 aac(30)-IV
ES22 Sardina pilchardus CTX CAZ FEP NAL OFX SXT A ST 471 CTX-M-15 –
ESBL, extended-spectrum β-lactamase; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; NET, netilmicin; GMI, gentamicin; KNM, kanamycin; OFX, oﬂoxacin; CIP, ciproﬂoxacin;
NAL, nalidixic acid; SXT, co-trimoxazole; PMQR, plasmid-mediated quinolone resistance.
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prevalence of aac60-Ib-cr was 22.7% of the strains. No isolates
carried qnrA or qepA genes. Resistance to aminoglycoside was
associated with the presence of aac(30)-IV (n = 6, 27.3%),
aac(20)-III (n = 5, 22.7%), aac(30)-II (n = 4, 18.2%), ant-(2”)-I
(n = 2, 9.1%), and aac(30)-I (n = 1, 4.5%) genes. Finally, 14
(63.6%) of the studied isolates harboured multiple resistant
genes (Table 1).
The 22 ESBL-producing isolates scattered among all four
major phylogenetic groups described in E. coli: 59.1% (n = 13)
belonged to A, 18.2% (n = 4) to D, 13.6% (n = 3) to B2, and
9.1% (n = 2) to B1. Three CTX-M-15-producing strains dis-
played serogroup O25. Among them, two (ES11, ES13) were
B2 phylogroup and belonged to the intercontinental E. coli clone
O25b:H4-ST131. They harboured multiple antibiotic resistance
genes. The remaining O25 positive strain was of phylogroup D.
Rep-PCR revealed a great genomic diversity of the ESBL-
producing E. coli isolates as they were classiﬁed into 14 pro-
ﬁles. However, Rep-PCR also displayed ﬁve clusters (>95%
similarity) of isolates, including two or more isolates (deﬁned as
major clonal groups), CV (n = 5; phylogenetic group A), CII and
CIII (each n = 2; D), CI (n = 2; B2), and CVI (n = 2; A). The
residual proﬁles contained single isolates (9 Rep-PCR patterns).
The ﬁve major clonal groups belonged, respectively, to
sequence types ST471 (n = 7), ST31 (n = 2), ST131 (n = 2),
ST398 (n = 3), and ST477 (n = 2), and the others were mainly of
ST132, ST37, ST8, ST21, ST74, and ST66 (Table 1). No seasonal
link between strains could be demonstrated.Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobiologyThis report documents for the ﬁrst time that wild ﬁsh in the
Mediterranean Sea are reservoirs of plasmid-mediated oxy-
imino-cephalosporin-, aminoglycoside-, and quinolone-resistant
E. coli, including pandemic clone B2-O25b:H4-ST131. We could
suggest that these isolates were most likely derived from
contamination of the ﬁsh from human sewage via river water
and a growing amount of waste from land urban, industrial, and
agricultural operation discharged untreated into the sea near
the coast in the regions of the Mediterranean Sea. Our ﬁndings
favour the hypothesis that natural environments are potent
reservoirs of multi-drug-resistant bacteria and associated genes.
Moreover, efforts should be made to more closely control the
antibiotic use and untreated waste, as this represents the major
reservoir of resistance genes and a human threat for the future.Transparency declarationINSERMU1047 is supported by INSERM and Université de
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